| Literature DB >> 24775713 |
Harutaka Katano1, Tsunekazu Hishima, Makoto Mochizuki, Yoshinori Kodama, Naoki Oyaizu, Yasunori Ota, Sohtaro Mine, Toru Igari, Atsushi Ajisawa, Katsuji Teruya, Junko Tanuma, Yoshimi Kikuchi, Tomoko Uehira, Takuma Shirasaka, Tomohiko Koibuchi, Aikichi Iwamoto, Shinichi Oka, Hideki Hasegawa, Seiji Okada, Akira Yasuoka.
Abstract
BACKGROUND: Opportunistic infections and malignancies such as malignant lymphoma and Kaposi sarcoma are significant complications of human immunodeficiency virus (HIV) infection. However, following the introduction of antiretroviral therapy in Japan in 1997, the incidence of clinical complications has decreased. In the present study, autopsy cases of HIV infection in Japan were retrospectively investigated to reveal the prevalence of opportunistic infections and malignancies.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24775713 PMCID: PMC4016795 DOI: 10.1186/1471-2334-14-229
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Characteristics of the patients infected with HIV
| Total | | 225* | 100% | 136 | 100% | 66 | 100% | |
| Sex | Male | 214 | 95.1% | 128 | 94.1% | 63 | 95.5% | 0.695** |
| | Female | 11 | 4.9% | 8 | 5.9% | 3 | 4.5% | |
| Age at death | <10 years | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | |
| | 11–20 | 2 | 0.9% | 2 | 1.5% | 0 | 0.0% | |
| | 21–30 | 30 | 13.3% | 22 | 16.2% | 6 | 9.1% | |
| | 31–40 | 60 | 26.7% | 34 | 25.0% | 19 | 28.8% | |
| | 41–50 | 69 | 30.7% | 48 | 35.3% | 14 | 21.2% | |
| | 51–60 | 34 | 15.1% | 18 | 13.2% | 14 | 21.2% | |
| | 61–70 | 24 | 10.7% | 10 | 7.4% | 10 | 15.2% | |
| | 71–80 | 5 | 2.2% | 1 | 0.7% | 3 | 4.5% | |
| | >81 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | |
| | Unknown | 1 | 0.4% | 1 | 0.7% | 0 | 0.0% | |
| Risk factor | Homosexual | 80 | 35.6% | 52 | 38.2% | 24 | 36.4% | 0.800** |
| | Heterosexual | 38 | 16.9% | 24 | 17.6% | 10 | 15.2% | |
| | Blood product | 37 | 16.4% | 29 | 21.3% | 7 | 10.6% | |
| | Other | 9 | 4.0% | 5 | 3.7% | 4 | 6.1% | |
| | Unknown | 61 | 27.1% | 26 | 19.1% | 21 | 31.8% | |
| CD4 count before death | <50 cells/μL | 122 | 54.2% | 80 | 58.8% | 33 | 50.0% | 0.639*** |
| 51–100 | 25 | 11.1% | 11 | 8.1% | 14 | 21.2% | | |
| 101–200 | 13 | 5.8% | 4 | 2.9% | 9 | 13.6% | | |
| 201–300 | 5 | 2.2% | 5 | 3.7% | 0 | 0.0% | | |
| 301–400 | 3 | 1.3% | 1 | 0.7% | 2 | 3.0% | | |
| >401 | 4 | 1.8% | 1 | 0.7% | 3 | 4.5% | | |
| Unknown | 53 | 23.6% | 34 | 25.0% | 5 | 7.6% | ||
ART, antiretroviral therapy. ART (+) patients were defined as patients who received any ART during their lifetime, whereas ART (−) patients were as patients who did not receive any ART in their lifetime.
*Total number of patients = 225 and included 23 patients with unknown ART status.
**P values were calculated for the rates of male or homosexuals between ART (−) and (+) patients by Chi-square test.
***P values were calculated for age or CD4 counts between all ART (−) and (+) patients by Mann–Whitney U-test. Bold font indicates statistical significance.
Figure 1Annual number and mean age of AIDS-related autopsies. The solid line indicates total number of AIDS autopsies in each year. The gray area indicates the number of patients on ART in these autopsy cases. The broken bar indicates the mean age.
Infectious diseases and malignancies in AIDS-associated autopsies
| | | | ||||||
|---|---|---|---|---|---|---|---|---|
| Total | 225 | 100.0% | 136 | 100.0% | 66 | 100.0% | | |
| Infectious diseases | | | | | | | | |
| Cytomegalovirus | 142 | 63.1% | 97 | 71.3% | 25 | 37.9% | | |
| | 66 | 29.3% | 43 | 31.6% | 11 | 16.7% | | |
| Non-tuberculous mycobacterium | 31 | 13.8% | 20 | 14.7% | 8 | 12.1% | 0.618 | |
| | 25 | 11.1% | 17 | 12.5% | 6 | 9.1% | 0.474 | |
| | 24 | 10.7% | 17 | 12.5% | 4 | 6.1% | 0.160 | |
| Human immunodeficiency virus encephalopathy | 21 | 9.3% | 13 | 9.6% | 6 | 9.1% | 0.915 | |
| | 16 | 7.1% | 11 | 8.1% | 3 | 4.5% | 0.526 | Y |
| Hepatitis B virus | 12 | 5.3% | 6 | 4.4% | 5 | 7.6% | 0.549 | Y |
| Herpes simplex virus | 12 | 5.3% | 1 | 0.7% | 1 | 1.5% | 0.816 | Y |
| Toxoplasmosis | 11 | 4.9% | 9 | 6.6% | 3 | 4.5% | 0.789 | Y |
| Hepatitis C virus | 9 | 4.0% | 3 | 2.2% | 5 | 7.6% | 0.147 | Y |
| Progressive multifocal leukoencephalopathy | 8 | 3.6% | 4 | 2.9% | 2 | 3.0% | 0.684 | Y |
| Tuberculosis | 6 | 2.7% | 4 | 2.9% | 0 | 0.0% | 0.385 | Y |
| Varicella zoster virus | 4 | 1.8% | 2 | 1.5% | 2 | 3.0% | 0.835 | Y |
| Multicentric Castleman disease | 2 | 0.9% | 1 | 0.7% | 1 | 1.5% | 0.816 | Y |
| Malignancies | | | | | | | | |
| Non Hodgkin lymphoma | 71 | 31.6% | 41 | 30.1% | 25 | 37.9% | 0.272 | |
| Kaposi sarcoma | 38 | 16.9% | 22 | 16.2% | 10 | 15.2% | 0.852 | |
| Endocervical cancer | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | – | |
| Non-AIDS defining malignancies | 20 | 8.9% | 10 | 7.4% | 10 | 15.2% | 0.082 | |
| Hepatic cancer | 8 | 3.6% | 4 | 2.9% | 4 | 6.1% | 0.495 | Y |
| Lung cancer | 6 | 2.7% | 2 | 1.5% | 4 | 6.1% | 0.174 | Y |
| Leukemia | 2 | 0.9% | 0 | 0.0% | 2 | 3.0% | 0.200 | Y |
| Hodgkin lymphoma | 2 | 0.9% | 1 | 0.7% | 1 | 1.5% | 0.816 | Y |
| Gastric cancer | 1 | 0.4% | 1 | 0.7% | 0 | 0.0% | 0.711 | Y |
| Other cancer | 3 | 1.3% | 3 | 2.2% | 0 | 0.0% | 0.551 | Y |
P values were calculated by Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance. ART, antiretroviral therapy. Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.
Figure 2Distribution of cytomegalovirus and . (A) CMV positive rate in each organ. Black bar indicates the CMV positive rate in each organ from 142 CMV-positive patients. Because CMV was detected in more than one organ per patient, the sum of the black bars is over 100%. (B) The positive rate of Candida albicans in each organ. Black bar indicates the positive rate of Candida albicans per organ from 25 Candida albicans-positive patients.
Non-Hodgkin lymphoma and Kaposi sarcoma in AIDS-associated autopsies
| | | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| All NHL cases | | 71 | 100.0% | 41 | 100.0% | 25 | 100.0% | | |
| Histology | DLBCL | 53 | 74.6% | 30 | 73.2% | 18 | 72.0% | 0.917 | |
| | BL | 4 | 5.6% | 3 | 7.3% | 1 | 4.0% | 0.987 | Y |
| | PEL | 5 | 7.0% | 4 | 9.8% | 1 | 4.0% | 0.706 | Y |
| | PBL | 1 | 1.4% | 1 | 2.4% | 0 | 0.0% | 0.801 | Y |
| | Other | 6 | 8.5% | 2 | 4.9% | 4 | 16.0% | 0.279 | Y |
| | Unknown | 2 | 2.8% | 1 | 2.4% | 1 | 4.0% | 0.703 | Y |
| Site | Nodular | 1 | 1.4% | 0 | 0.0% | 1 | 4.0% | 0.801 | Y |
| | Extranodular | 45 | 63.4% | 28 | 68.3% | 12 | 48.0% | 0.102 | |
| | Both | 21 | 29.6% | 11 | 26.8% | 10 | 40.0% | 0.265 | |
| | Unknown | 4 | 5.6% | 2 | 4.9% | 2 | 8.0% | 0.987 | Y |
| PCNS | Yes | 27 | 38.0% | 18 | 43.9% | 6 | 24.0% | 0.103 | |
| EBV | Positive | 52 | 73.2% | 35 | 85.4% | 12 | 48.0% | | |
| KSHV | Positive | 6 | 8.5% | 5 | 12.2% | 1 | 4.0% | 0.495 | Y |
| Cause of death | Yes | 50 | 70.4% | 33 | 80.5% | 16 | 64.0% | 0.137 | |
| All KS cases | | 38 | | 22 | | 10 | | | |
| Site | Skin | 32 | 84.2% | 19 | 86.4% | 9 | 90.0% | 0.410 | |
| | GI tract | 27 | 71.1% | 15 | 68.2% | 8 | 80.0% | 0.705 | |
| | Lung | 21 | 55.3% | 11 | 50.0% | 6 | 60.0% | 0.799 | |
| | Lymph node | 20 | 52.6% | 13 | 59.1% | 6 | 60.0% | 0.502 | |
| | Other | 16 | 42.1% | 0 | 0.0% | 0 | 0.0% | 0.787 | Y |
| Cause of death | Yes | 11 | 29.0% | 7 | 31.8% | 2 | 20.0% | 0.791 | Y |
NHL, Non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; PEL, primary effusion lymphoma; PBL, plasmablastic lymphoma; PCNS, primary central nervous system lymphoma; EBV, Epstein–Barr virus; KSHV, Kaposi sarcoma-associated herpes virus; KS, Kaposi sarcoma; GI, gastrointestinal. P values were calculated by Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance.
Lung disease in patients infected with HIV
| Any illness | 173 | 76.9% |
| Cytomegalovirus infection | 93 | 41.3% |
| 66 | 29.3% | |
| Any bacterial pneumonia | 31 | 13.8% |
| 23 | 10.2% | |
| Kaposi sarcoma | 21 | 9.3% |
| Non-tuberculous mycobacterium infection | 14 | 6.2% |
| 11 | 4.9% | |
| 10 | 4.4% | |
| Tuberculosis | 4 | 1.8% |
Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.
Brain disease in patients infected with HIV
| Any illness | 85 | 49.4% |
| Cytomegalovirus infection | 45 | 26.1% |
| Malignant lymphoma | 26 | 15.1% |
| HIV encephalopathy | 21 | 12.2% |
| Progressive multifocal leukoencephalopathy | 8 | 4.7% |
| Toxoplasmosis | 8 | 4.7% |
| Non-tuberculous mycobacterium infection | 4 | 2.3% |
| 2 | 1.2% | |
| Varicella zoster virus infection | 2 | 1.2% |
| Herpes simplex virus infection | 1 | 0.6% |
| Glioblastoma | 1 | 0.6% |
| 1 | 0.6% |
Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.
Cause of death in AIDS-associated autopsies
| | | | ||||||
|---|---|---|---|---|---|---|---|---|
| Total* | 225 | 100.0% | 136 | 100.0% | 66 | 100.0% | | |
| Malignant lymphoma | 50 | 22.2% | 33 | 24.3% | 16 | 24.2% | 0.997 | |
| Cytomegalovirus | 44 | 19.6% | 27 | 19.9% | 9 | 13.6% | 0.279 | |
| Pneumonia | 31 | 13.8% | 19 | 14.0% | 9 | 13.6% | 0.949 | |
| 30 | 13.3% | 21 | 15.4% | 4 | 6.1% | 0.058 | | |
| Non-tuberculous mycobacterium | 12 | 5.3% | 10 | 7.4% | 2 | 3.0% | 0.367 | Y |
| Kaposi sarcoma | 11 | 4.9% | 7 | 5.1% | 2 | 3.0% | 0.749 | Y |
| Progressive multifocal leukoencephalopathy | 8 | 3.6% | 4 | 2.9% | 2 | 3.0% | 0.684 | Y |
| Cancer | 8 | 3.6% | 2 | 1.5% | 6 | 9.1% | Y | |
| Hepatitis | 8 | 3.6% | 3 | 2.2% | 4 | 6.1% | 0.320 | Y |
| 7 | 3.1% | 6 | 4.4% | 0 | 0.0% | 0.197 | Y | |
| Kidney failure | 7 | 3.1% | 4 | 2.9% | 3 | 4.5% | 0.861 | Y |
| HIV encephalopathy | 7 | 3.1% | 5 | 3.7% | 2 | 3.0% | 0.861 | Y |
| 6 | 2.7% | 5 | 3.7% | 0 | 0.0% | 0.274 | Y | |
| Toxoplasmosis | 4 | 1.8% | 3 | 2.2% | 1 | 1.5% | 0.835 | Y |
| Tuberculosis | 3 | 0.9% | 2 | 1.5% | 0 | 0.0% | 0.816 | Y |
| Sepsis | 3 | 1.3% | 2 | 1.5% | 1 | 1.5% | 0.551 | Y |
| 3 | 1.3% | 2 | 1.5% | 0 | 0.0% | 0.816 | Y | |
| Varicella zoster virus | 2 | 1.3% | 1 | 0.7% | 1 | 1.5% | 0.816 | Y |
| 1 | 0.4% | 1 | 0.7% | 0 | 0.0% | 0.711 | Y | |
| Histoplasma | 1 | 0.4% | 1 | 0.7% | 0 | 0.0% | 0.711 | Y |
*Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.
HIV, human immunodeficiency virus. P values were calculated with the Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance.